Pfizer (NYSE:PFE | PFE Price Prediction) and Moderna (NASDAQ:MRNA) just closed the books on Q4 2025, and the contrast is ...

Quick Read Moderna (MRNA) stock surged on renewed Hantavirus vaccine interest following a cruise ship outbreak, with Q1 ...

RNA rewards companies that can integrate biology, data science, manufacturing, and clinical development into a single adaptive engine. Pharma is moving into a new phase of competition one shaped less ...

Pfizer is by far the larger and better-established drugmaker. With a market cap of $156 billion, the pharmaceutical leader boasts a deep product portfolio across several therapeutic areas. Even with a ...

LONDON (Reuters) -Pfizer and its German partner BioNTech on Friday lost their bid to overturn a ruling that their COVID-19 vaccine infringed one of Moderna's patents at London's Court of Appeal. Last ...

Shares of Pfizer and Moderna fell on Friday after a report that Trump administration health officials plan to link Covid vaccines to the deaths of 25 children. The report comes as Health and Human ...

Moderna is suing Pfizer and BioNTech for infringing patents central to Moderna's mRNA technology platform used to develop the COVID vaccine, the company said in a press release Friday. A widely ...

Shares in Pfizer and Moderna fell 3.9% and 7.4%, respectively, Friday after a report that the Trump administration plans to link the deaths of 25 children to COVID vaccines. Trump health officials ...

The smaller, more volatile of these two companies has higher potential for significant gains. However, that also comes with a healthy dose of risk. Choosing between these two stocks may come down to ...